A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Oliceridine (Primary) ; Morphine
  • Indications Postoperative pain
  • Focus Registrational; Therapeutic Use
  • Acronyms APOLLO-2
  • Sponsors Trevena
  • Most Recent Events

    • 03 Aug 2017 According to a Trevena media release, data from the study has been presented at the 32nd Annual Meeting of the Society for Ambulatory Anesthesia (SAMBA) and the 36th Annual Scientific Meeting of the American Pain Society (APS).
    • 04 May 2017 According to a Trevena media release, data from this trial will be prented at sponsored symposium entitled Consequences of Poorly Controlled Acute Pain and New Frontiers in Opioid Pharmacotherapy.
    • 06 Apr 2017 Results presented at the 42nd Annual Regional Anesthesiology and Acute Pain Medicine Meeting 2017, according to a Trevena media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top